Interview with Bart Rossel, Managing Director, Oystershell
Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated…
Address: Booiebos 24, B-9031 Drongen, ,Belgium
Tel: +32 9 377 24 85
Web: http://www.oystershell.com/en
Oystershell is an independent developer of over-the counter health products. We invent and develop pharmaceutical products such as traditional medicines, medical devices, biocides, dietary supplements and cosmetics. Oystershell develops and offers new products and exclusive licenses to help grow the brands of our marketing partners
Pharmaceutical product development generally does not leave a lot of room for creativity and yet we made this exactly the core of our business. Our team of scientists innovates OTC products with unique consumer benefits, sound scientific proof, regulatory approval, and all the conventional quality standards that the pharmaceutical world expects (GMP, ISO13485, HACCP).
Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated…
The EU biopharmaceutical ecosystem is currently languishing in third place globally. EUCOPE’s Alexander Natz discusses how the European Commission’s most fundamental review of the pharmaceutical legislation in decades is supposed…
EUCOPE’s Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new…
In an extensive recent PharmaBoardroom conversation, EMA Head of Advanced Therapies Ana-Hidalgo-Simon highlighted some of the most important trends around advanced therapy regulation in Europe. Hidalgo-Simon touched on why moderate…
Speaking exclusively to PharmaBoardroom, the EMA’s Head of Advanced Therapies Ana Hidalgo-Simon discusses steadily growing numbers of regulatory applications in the advanced therapy field, the vital importance of patient group…
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
The new Belgian government has moved to streamline its response to the COVID-19 crisis with the appointment of Pedro Facon, director general for health at Belgium’s Federal Public Service Health…
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and…
Kevin Houdenaert, general manager for Benelux and the Nordics at Italian rare disease, specialty and primary care specialist Recordati, gives an overview of the market access specificities of the markets…
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Belgium is a vitally important country for Johnson & Johnson’s pharmaceutical arm, Janssen, globally. In addition to their R&D centre and a pharma production plant in Beerse, Janssen also has…
Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship…
See our Cookie Privacy Policy Here